SCHEMBL3597849

SCHEMBL3597849

CCOC(=O)C(O)(c1cn(Cc2ccccc2)c2cc(C(=O)OCc3ccccc3)ccc12)C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 1/20 0.46
S1PR3 Q99500 4/20 0.40
GLA P06280 1/20 0.39
PTPN1 P18031 1/20 0.39
MAPT P10636 4/20 0.39
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
CNR2 P34972 1/20 0.39
TP53 P04637 1/20 0.39
SERPINE1 P05121 1/20 0.39
LMNA P02545 2/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
P2RX3 P56373 1/20 0.39
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3598928 0.93 F2RL3 (0.48) F2RL3PTPN1MAPTCNR2TP53
SCHEMBL3598494 0.91 F2RL3 (0.45) F2RL3GLAPTPN1MAPTPDE4A
SCHEMBL3600955 0.86 PPARG (0.49) GLAPTPN1CNR2SERPINE1LMNA
SCHEMBL3600671 0.86 PTPN1 (0.47) F2RL3GLAPTPN1MAPTSERPINE1
SCHEMBL3600338 0.86 GLA (0.43) F2RL3GLAPTPN1SERPINE1KMT2A
SCHEMBL3602094 0.85 GLA (0.42) F2RL3GLAPTPN1PDE4APDE4B
SCHEMBL3592319 0.84 GLA (0.52) F2RL3GLAPTPN1CNR2TP53
SCHEMBL3588733 0.83 MAPK1 (0.42) F2RL3GLAPTPN1MAPTPDE4A
SCHEMBL3583780 0.83 F2RL3 (0.47) F2RL3GLAPTPN1MAPTTP53
SCHEMBL3596187 0.83 GLA (0.40) F2RL3GLAPTPN1MAPTSERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 F2RL3 555/4885S1PR3 2176/4885GLA 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.